Skip to main content

Advertisement

SpringerLink
Log in

Prognostic significance of the baseline serum uric acid level in non-small cell lung cancer patients treated with first-line chemotherapy: a study of the Turkish Descriptive Oncological Researches Group

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Non-small cell lung cancer (NSCLC) is one of the most common cancers. Most of the patients are inoperable at the time of diagnosis, and the prognosis is poor. Many prognostic factors have been identified in prior studies. However, it is not clear which factor is more useful. In this study, we investigated whether uric acid, the last breakdown product of purine metabolism in humans, has a prognostic significance in advanced NSCLC. A total of 384 NSCLC patients at stage IIIB/IV and who did not meet exclusion criteria were included in this retrospective cross-sectional study. The patients’ serum uric acid levels before first-line chemotherapy and demographic (age, gender, smoking), clinical (performance status, weight loss, disease stage, first-line treatment regimen), laboratory (hemoglobin, lactate dehydrogenase), and histologic (histologic type, tumor grade) characteristics were recorded. First, a cut-off value was determined for serum uric acid level. Then, the patients were stratified into four groups (quartiles) based on their serum uric acid levels. Descriptive statistics, univariate and multivariate analyses, and survival analyses were used. Majority of the patients were males, smokers and metastatic at time of diagnosis and had history of weight loss and adenocarcinoma upon pathological examination. The serum uric acid levels of all patients were determined as 4.9 ± 2.9 (range 1.9–11.3). The patients were stratified according to quartiles of serum uric acid concentration with cutoff values defined as <3.08 mg/dL (lowest quartile, Group 1), 3.09–5.91 mg/dL (Group 2), 5.92–7.48 mg/dL (Group 3), and >7.49 mg/dL (highest quartile, Group 4). Among the patients who had serum uric acid levels over 7.49, it was observed that those who also had squamous cell carcinoma had a greater rate of brain metastasis, a shorter time lapse until brain metastasis, and lower overall survival rate. It can be assumed that NSCLC patients who had histologically shown squamous cell carcinoma display brain metastasis and poor prognosis. It can be recommended to repeat this study with larger patient series including immunohistochemical, molecular, and wider laboratory investigations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.

    Article  PubMed  Google Scholar 

  2. Berghmans T, Paersmans M, Sculier JP. Prognostic factors in stage III non-small-cell lung cancer: a review on conventional, metabolic and new biological variables. Ther Adv Med Oncol. 2011;3:127–38.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Ademuyiva FO, Johnson CS, White AS, Breen TE, Harvej J, et al. Prognostic factors in stage III non-small-cell lung cancer. Clin Lung Cancer. 2007;8:478–82.

    Article  Google Scholar 

  4. Berghmans T, Mascaux C, Haller A, Meert AP, von Houtte P, et al. EGFR, TTF-1, and Mdm2 expression in satge III non-small-cell lung cancer: a positive association. Lung Cancer. 2008;62:35–44.

    Article  PubMed  CAS  Google Scholar 

  5. Betticher DC, Hsuschmitz SF, Totsch M, Hensen E, Joss C, et al. Prognostic factors affecting long-term outcomes in patients with resected stage IIIA, pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer. 2006;94:1099–106.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  6. Brundage MD, Dovies D, Mackillop WJ. Prognostic factors in non-small-cell lung cancer: a decade of progress. Chest. 2002;122:1037–57.

    Article  PubMed  Google Scholar 

  7. Tanako F, Yanagihana K, Otake Y, Kawano Y, Miyahana R, et al. Prognostic factors in resected pathologic (p-) stage IIIA, N2 non-small cell lung cancer. Ann Surg Oncol. 2004;11:612–8.

    Article  Google Scholar 

  8. Martins SJ, Peresna JR. Clinical factors and prognosis in non-small cell lung cancer. Am J Clin Oncol. 1999;22:453–7.

    Article  PubMed  CAS  Google Scholar 

  9. Seculier JP, Chansky K, Crowley JJ, van Meerbeeck J, Goldshow P. The impact of additional prognostic factors on survival and their relationship with the anatomical extend of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposal for the 7th Edition. J Thorac Oncol. 2008;3:457–66.

    Article  Google Scholar 

  10. Choi YS, Shim YM, Kim J, Kim K. Recurrence-free survival and prognostic factors in resected pN2 non-small cell lung cancer. Eur J Cardiothorac Surg. 2002;22(695–700):11.

    Google Scholar 

  11. Fini MA, Elias A, Johnson RJ, Wright RM. Contribution of uric acid to cancer risk, recurrence, and mortality. Clin Transl Med. 2012;1:16–30.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Petersson B, Trell E. Raised serum urate concentration as risk factor for premature mortality in middle-age men: relation to death from cancer. Br Med J (Clin Res Ed). 1983;287:7–9.

    Article  CAS  Google Scholar 

  13. Petersson B, Trell E, Henningsen NC, Hood B. Risk factors for premature death in middle-age men. Br Med J (Clin Res Ed). 1984;288:1264–8.

    Article  CAS  Google Scholar 

  14. Levine W, Dyer AR, Shekelte RB, Schoenberger JA, Stanler J. Serum uric acid and 11.5-year mortality of middle-age women: findings of the Chicago Heart Association Detection Project in Industry. J Clin Epidemiol. 1989;42:257–67.

    Article  PubMed  CAS  Google Scholar 

  15. Ames BN, Catheart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA. 1981;78:6858–62.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  16. Shin HS, Lee HR, Lee DG, Shin JY, Cho KH, et al. Uric acid as a prognostic factor for survival time: a prospective cohort study of terminally ill cancer patients. J Pain Symptom Manage. 2006;31:493–501.

    Article  PubMed  CAS  Google Scholar 

  17. Giavonnucci E. Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr. 2007;83:s836–42.

    Google Scholar 

  18. Rose DP, Hoffner SM, Baillargeon J. Adiposity, the metabolic syndrome, and breast cancer in African–American and white American women. Endocr Rev. 2007;28:763–77.

    Article  PubMed  CAS  Google Scholar 

  19. Sun AS, Cederboum AI. Oxidoreductase activities in normal rat liver, tumor-bearing rat liver, and hepatoma HC-252. Cancer Res. 1980;40:4677–81.

    PubMed  CAS  Google Scholar 

  20. Ikegama T, Natsumeda Y, Weber G. Decreased concentration of xanthine dehydrogenase (EC 1.1.1.204) in rat hepatomas. Cancer Res. 1986;46:3838–41.

    Google Scholar 

  21. Lawol AO, Kolude B, Adeyemi BF. Serum uric acid levels in oral cancer patients seen at tertiary institution in Nigeria. Ann Ib Postgrad Med. 2012;10:9–12.

    Google Scholar 

  22. Bozkir A, Simsek D, Gungor A, Torun M. Ascorbic acid and uric acid levels in lung cancer patients. J Clin Pharm Ther. 1999;24:43–7.

    Article  PubMed  CAS  Google Scholar 

  23. Strasak AM, Rapp K, Hilbe W, Oberaigner W. The role of serum uric acid as an antioxidant protecting against cancer: prospective study in more than 28,000 older Austrian women. Ann Oncol. 2007;18:1893–7.

    Article  PubMed  CAS  Google Scholar 

  24. Wıllet WC, MacMahon B. Diet and cancer- an overview (first of two parts). N J Engl Med. 1984;310:633–8.

    Article  Google Scholar 

  25. Abdel-Salam OME, Youness ER, Hafez HF. The antioxidant status of the plasma in patients with breast cancer undergoing chemotherapy. J Mol Integr Physiol. 2011;1:29–35.

    Article  CAS  Google Scholar 

  26. Sevanian A, Davis KJ, Hochstein P. Serum urate as an antioxidant for ascorbic acid. Am J Clin Nutr. 1991;54:1129–11343.

    Google Scholar 

  27. Kolonel LN, Yoshisama C, Nomura AM, Stemmermann GN. Relationship of serum uric acid to cancer occurrence in a prospective male cohort. Cancer Epidemiol Biomarkers Prev. 1994;3:225–8.

    PubMed  CAS  Google Scholar 

  28. Cetin K, Ettinger DS, Hei YJ, O’Malley CD. Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology, and End results Program. Clin Epidemiol. 2011;3:139–48.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Franklin WA, Aisner DL, Varella-Garcia M. prognostic patterns in the histology of pulmonary adenocarcinoma. J Clin Oncol. 2012;30:1401–3.

    Article  PubMed  Google Scholar 

  30. Lortet-Tieulent J, Soerjomataram I, Ferlay J, Rutherford M, Weiderpass E, et al. International trends in lung cancer incidence by histological subtype: adenocarcinoma stabilizing in men but still increasing in women. Lung Cancer. 2014;84:13–22.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We would like to thank to Roche Oncology Department of Medical Support for translate to English.

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Faculty of Medicine, Sitki Kocman University, Mugla, Turkey

    Ozgur Tanriverdi

  2. Department of Medical Oncology, Kent Hospital, Izmir, Turkey

    Suna Cokmert

  3. Department of Medical Oncology, Faculty of Medicine, Adnan Menderes University, Aydın, Turkey

    Esin Oktay & Nezih Meydan

  4. Department of Medical Oncology, Faculty of Medicine, Bilim University, Istanbul, Turkey

    Kezban Nur Pilanci & Cetin Ordu

  5. Department of Medical Oncology, Faculty of Medicine, Celal Bayar University, Manisa, Turkey

    Serkan Menekse & Gamze Goksel

  6. Department of Medical Oncology, Education and Research Hospital, Sanliurfa, Turkey

    Muharrem Kocar

  7. Department of Radiation Oncology, Izmir University Medical Park Hospital, Izmir, Turkey

    Cenk Ahmet Sen

  8. Department of Medical Oncology, State Hospital, Balıkesir, Turkey

    Nilufer Avci

  9. Department of Medical Oncology, Tepecik Education and Research Hospital, Izmir, Turkey

    Tulay Akman

Authors
  1. Ozgur Tanriverdi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Suna Cokmert
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Esin Oktay
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kezban Nur Pilanci
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Serkan Menekse
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Muharrem Kocar
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Cenk Ahmet Sen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Nilufer Avci
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tulay Akman
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Cetin Ordu
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Gamze Goksel
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Nezih Meydan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ozgur Tanriverdi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tanriverdi, O., Cokmert, S., Oktay, E. et al. Prognostic significance of the baseline serum uric acid level in non-small cell lung cancer patients treated with first-line chemotherapy: a study of the Turkish Descriptive Oncological Researches Group. Med Oncol 31, 217 (2014). https://doi.org/10.1007/s12032-014-0217-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-014-0217-z

Keywords

Search

Navigation